• +1-646-491-9876
    • +91-20-67278686

    Search

    Familial Adenomatous Polyposis - Pipeline Review, H1 2017

    Familial Adenomatous Polyposis - Pipeline Review, H1 2017

    • Report Code ID: RW0001689460
    • Category Healthcare
    • No. of Pages 39
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.

    Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or Gardner syndrome. Familial adenomatous polyposis (FAP) is an inherited disorder characterized by cancer of the large intestine (colon) and rectum. People with the classic type of familial adenomatous polyposis may begin to develop multiple noncancerous (benign) growths (polyps) in the colon as early as their teenage years. Unless the colon is removed, these polyps will become malignant (cancerous). Symptoms may include bleeding from the rectum, change in bowel habits, abdominal pain, low blood counts or unexplained weight loss.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).
    - The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Familial Adenomatous Polyposis - Overview
    Familial Adenomatous Polyposis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Familial Adenomatous Polyposis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development
    Cancer Prevention Pharmaceuticals Inc
    Marina Biotech Inc
    Thetis Pharmaceuticals LLC
    Familial Adenomatous Polyposis - Drug Profiles
    (celecoxib + lisinopril) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (eflornithine hydrochloride + sulindac) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEQ-508 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EM-011 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pyrvinium pamoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-252 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Familial Adenomatous Polyposis - Dormant Projects
    Familial Adenomatous Polyposis - Discontinued Products
    Familial Adenomatous Polyposis - Product Development Milestones
    Featured News & Press Releases
    Apr 14, 2016: Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
    Apr 04, 2016: Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
    Jan 27, 2016: Thetis Pharmaceuticals Awarded Key Patent for TP-252
    Jan 19, 2016: Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
    Oct 15, 2015: Thetis Pharmaceuticals Presents at BIO Investor Forum in San Francisco
    Aug 04, 2015: Thetis Receives Notice of Allowance for Patent Covering Pharmaceutical Composition of Novel Mineral Amino Acid Derivative TP-252
    Dec 05, 2013: Phase III Familial Adenomatous Polyposis Trial Now Open for Enrollment
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Familial Adenomatous Polyposis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
    Familial Adenomatous Polyposis - Pipeline by Marina Biotech Inc, H1 2017
    Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, H1 2017
    Familial Adenomatous Polyposis - Dormant Projects, H1 2017
    Familial Adenomatous Polyposis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Familial Adenomatous Polyposis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Cancer Prevention Pharmaceuticals Inc
    Marina Biotech Inc
    Thetis Pharmaceuticals LLC

    Request for Sample

    Report Url http://www.reportsweb.com//familial-adenomatous-polyposis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//familial-adenomatous-polyposis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//familial-adenomatous-polyposis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments